You Searched For: PD-173955

Supplier: BeanTown Chemical

Description: CAS: 7440-05-3; EC No: 231-115-6; MDL No: MFCD00011167 Solid; Molecular Formula: Pd; MW: 106.42 Melting Point: 1554°; Boiling Point: 2970° Density (g/mL): 12.02

SDS

Catalog Number: (10797-798)

Supplier: Prosci

Description: Programmed cell death 1 ligand 2 (PD-L2 or PDCD1 ligand 2) is also known as Butyrophilin B7-DC, CD antigen CD273, which belongs to the immunoglobulin superfamily or BTN/MOG family. The expression of PD-L2 is up-regulated by IFNG/IFN-gamma stimulation in monocytes and induced on dendritic cells grown from peripheral blood mononuclear cells with CSF2 and IL-4. PD-L2 Involved in the costimulatory signal, essential for T-cell proliferation and IFNG production in a PDCD1-independent manner. PD-L2 interaction with PDCD1 inhibits T-cell proliferation by blocking cell cycle progression and cytokine production.

Catalog Number: (10749-174)

Supplier: Prosci

Description: PD-1 Monoclonal Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antig en-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PDL-1 and PDL-2. Upon binding to either of these ligands, signals generated by PD-1 inhibit the activation of the immune response in the absence of "danger signals" such as LPS or other molecules associated with bacteria or other pathogens. Evidence for this is seen in PD1-null mice who exhibit hyperactivated immune systems and autoimmune diseases. Despite its predicted molecular weight, PD-1 often migrates at higher molecular weight in SDS-PAGE.

Supplier: Thermo Scientific Chemicals

Description: 99.99 5G

SDS Certificates

Supplier: Thermo Scientific Chemicals

Description: MDL: MFCD00011167

SDS Certificates

Supplier: Thermo Scientific Chemicals

Description: MDL: MFCD00011167

SDS Certificates

Supplier: Thermo Scientific Chemicals

Description: [1,4-Bis(diphenylphosphino)butane]palladium(II) dichloride (17,6% Pd)

SDS Certificates

Supplier: BeanTown Chemical

Description: CAS: 7440-05-3; EC No: 231-115-6; MDL No: MFCD00011167; RTECS: RT3480500 UN No: UN3089; Haz Class: 4.1; Packing Group: II Powder; Molecular Formula: Pd; MW: 106.42 Melting Point: 1554°; Boiling Point: 2970° Density (g/mL): 12.02

SDS

Supplier: Ambeed

Description: Palladium(II) iodide 98%

New Product

Supplier: Thermo Scientific Chemicals

Description: MDL: MFCD00010884

SDS Certificates

Catalog Number: (MSPP-7126B701M)

Supplier: R&D Systems

Description: The Recombinant Human VISTA/B7-H5/PD-1H Fc Chimera Protein from R&D Systems is derived from NS0. The Recombinant Human VISTA/B7-H5/PD-1H Fc Chimera Protein has been validated for the following applications: Bioactivity.

Supplier: Ricca Chemical

Description: 1000 ppm Pd ion in dilute HCl. For use in standardizing atomic absorption spectrophotometers. 100mL.

SDS Certificates

Supplier: VWR International

Description: DuraChill® chillers provide stable and reliable cooling for various common heat removal applications, including laser etching, AA furnaces, ICP, rotary evaporators, vacuum systems, reaction vessels, plasma etching, and condenser cooling.

Catalog Number: (10797-762)

Supplier: Prosci

Description: Programmed cell death protein 1 (PD-1) is also known as CD279 and PDCD1, is a type I membrane protein and is a member of the extended CD28/CTLA-4 family of T cell regulators. PDCD1 is expressed on the surface of activated T cells, B cells, macrophages, myeloid cells and a subset of thymocytes. PD-1 has two ligands, PD-L1 and PD-L2, which are members of the B7 family. PD-L1 is expressed on almost all murine tumor cell lines, including PA1 myeloma, P815 mastocytoma, and B16 melanoma upon treatment with IFN-?. PD-L2 expression is more restricted and is expressed mainly by DCs and a few tumor lines. PD1 inhibits the T-cell proliferation and production of related cytokines including IL-1, IL-4, IL-10 and IFN-? by suppressing the activation and transduction of PI3K/AKT pathway. In addition, coligation of PD1 inhibits BCR-mediating signal by dephosphorylating key signal transducer. In vitro, treatment of anti-CD3 stimulated T cells with PD-L1-Ig results in reduced T cell proliferation and IFN-? secretion. Monoclonal antibodies targeting PD-1 that boost the immune system are being developed for the treatment of cancer.

Catalog Number: (76163-668)

Supplier: Prosci

Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC) (1). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC (2). PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells (3). This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts. PD-L1 also functions as an immune checkpoint protein, and multiple anti-PD-L1 antibodies are currently in phase II and III clinical trials, with one antibody already approved for the treatment of cancer (4).

Catalog Number: (76163-570)

Supplier: Prosci

Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC) (1). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC (2). PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells (3). This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts. PD-L1 also functions as an immune checkpoint protein, and multiple anti-PD-L1 antibodies are currently in phase II and III clinical trials, with one antibody already approved for the treatment of cancer (4).